The first patient has been dosed in the P-II (SOLSTICE) trial evaluating the safety, tolerability & efficacy of VIR-2218 and VIR-3434 as monothx. & in combination with adult patients aged 18 to 69yrs. for chronic HDV for ~88wks. The initial results are expected in 2023
The 1EPs of the trial is the proportion of patients who achieve a ≥2log10 decrease in HDV RNA over baseline or HDV RNA less than the limit of quantification & normalization of ALT @24wk. along with a proportion of patients with TEAE & SAEs
VIR-2218 & VIR-3434 are also being studied in the P-II (MARCH) trial for HBV. The part A results of the (MARCH) trial showed that the combination therapy resulted in an ~3 log decline in HBsAg
Ref: Globenewswire | Image: Vir Biotechnology
